Skip to content

US · LFWD · MEDICAL - DEVICES

Lifeward Ltd. (LFWD) intrinsic value and stock valuation

$2.80as of 2026-11-21 · Mkt cap 12.38M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lifeward Ltd. DCF and intrinsic value

InvestorsCraft values LFWD with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from LFWD’s statements →

Lifeward Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Yokneam Illit, MA 2069203 golifeward.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$22M+38.1% 5y CAGRd
20162025
Net income
-$-19.91M
20162025
Free cash flow
-$-16.83M
20162025
Total equity
$8.41M-17.3% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$22M$25.7M$13.9M$5.51M$5.97M
Operating income-$-16.89M-$-19.55M-$-23.61M-$-19.1M-$-12.65M
Net income-$-19.91M-$-28.94M-$-22.13M-$-19.57M-$-12.74M
EPSd-$-1.71M-$-40.19M-$-31.17M-$-26.45M-$-22.35M
Operating cash flow-$-16.83M-$-21.72M-$-20.67M-$-17.89M-$-11.47M
Capital expenditure-$-20K$0.00-$-80K-$-30K-$-50K
Free cash flow-$-16.83M-$-21.72M-$-20.75M-$-17.92M-$-11.52M
Total assets$22.9M$30.5M$63.2M$74.2M$94.8M
Total debt$4.39M$880K$1.9M$900K$1.06M
Net debt$2.22M-$-6.06M-$-26.18M-$-67M-$-87.28M
Total equity$8.41M$18.9M$46.5M$68.2M$89.4M
Cash and short-term investments$2.17M$6.94M$28.1M$67.9M$88.3M
Income statement
20252024202320222021
Revenue$22M$25.7M$13.9M$5.51M$5.97M
Cost of revenue$13.6M$17.5M$9.4M$3.61M$3.06M
Gross profit$8.43M$8.22M$4.45M$1.91M$2.9M
Research and development expenses$3.25M$4.62M$4.15M$4.03M$2.94M
Selling, general and administrative expenses$22.1M$23.1M$23.9M$17M$12.6M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$25.3M$27.8M$28.1M$21M$15.6M
Cost and expenses$38.9M$45.2M$37.5M$24.6M$18.6M
Interest income$0.00$640K$1.35M$0.00$0.00
Interest expense$290K$130K$20K$20K$30K
Depreciation and amortization$330K$3.84M$1.85M$200K$270K
Ebitda-$-19.34M-$-24.93M-$-20.28M-$-18.9M-$-12.39M
Operating income-$-16.89M-$-19.55M-$-23.61M-$-19.1M-$-12.65M
Total other income/expenses, net-$-3.08M-$-9.35M$1.47M$0.00$10K
Income before tax-$-19.97M-$-28.9M-$-22.14M-$-19.1M-$-12.64M
Income tax expense-$-60K$40K-$-10K$470K$90K
Net income-$-19.91M-$-28.94M-$-22.13M-$-19.57M-$-12.74M
Weighted average shares outstanding$11.6M$720K$710K$740K$570K
Weighted average diluted shares outstanding$11.6M$720K$710K$740K$570K
Balance sheet
20252024202320222021
Cash and short-term investments$2.17M$6.94M$28.1M$67.9M$88.3M
Net receivables$6.14M$6M$3.12M$1.04M$580K
Inventory$5.73M$6.72M$5.65M$2.93M$2.99M
Total current assets$15.8M$21.3M$39.2M$72.5M$92.5M
Property, plant and equipment, net$2.13M$1.42M$3.12M$1.03M$1.17M
Goodwill and intangible assets$4.75M$7.54M$20.1M$0.00$0.00
Long-term investments$410K$360K$710K$660K$710K
Total non-current assets$7.09M$9.19M$24M$1.73M$2.23M
Total assets$22.9M$30.5M$63.2M$74.2M$94.8M
Accounts payable$5.59M$5.02M$5.07M$1.95M$1.38M
Short-term debt$3.23M$860K$1.3M$560K$640K
Deferred revenue$920K$1.25M$1.5M$300K$320K
Total current liabilities$12M$10.2M$11.8M$4.78M$4.04M
Long-term debt$1.16M$20K$610K$330K$420K
Deferred revenue, non-current$1.23M$1.32M$1.51M$890K$870K
Total non-current liabilities$2.45M$1.41M$4.89M$1.29M$1.33M
Capital lease obligations$1.58M$20K$1.9M$900K$1.06M
Total liabilities$14.5M$11.6M$16.7M$6.07M$5.37M
Common stock$9.42M$4.59M$4.49M$4.49M$4.66M
Retained earnings-$-284.74M-$-264.82M-$-235.88M-$-213.75M-$-194.18M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$8.41M$18.9M$46.5M$68.2M$89.4M
Total investments$410K$360K$710K$660K$710K
Total debt$4.39M$880K$1.9M$900K$1.06M
Net debt$2.22M-$-6.06M-$-26.18M-$-67M-$-87.28M
Cash flow statement
20252024202320222021
Net income-$-16.23M-$-28.94M-$-22.13M-$-19.57M-$-12.74M
Depreciation and amortization$330K$3.84M$1.85M$200K$270K
Stock-based compensation$740K$1.28M$1.33M$990K$830K
Change in working capital-$-300K-$-4.97M-$-1.34M$90K$200K
Accounts receivable-$-130K-$-2.88M-$-310K-$-410K$100K
Inventory$900K-$-920K-$-280K-$-120K$430K
Accounts payable-$-350K-$-50K$1.04M$570K-$-880K
Net cash provided by operating activities-$-16.83M-$-21.72M-$-20.67M-$-17.89M-$-11.47M
Investments in property, plant and equipment-$-20K$0.00-$-80K-$-30K-$-50K
Acquisitions, net$0.00$0.00-$-18.07M$0.00$0.00
Net cash used for investing activities-$-20K$0.00-$-18.15M-$-30K-$-50K
Common stock issued$9.2M$0.00$0.00$0.00$64.5M
Common stock repurchased$0.00$0.00-$-990K-$-2.5M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.2M$0.00-$-990K-$-2.5M$79.5M
Net change in cash-$-4.53M-$-21.68M-$-39.76M-$-20.5M$68M
Cash at end of period$2.58M$7.11M$28.8M$68.6M$89.1M
Operating cash flow-$-16.83M-$-21.72M-$-20.67M-$-17.89M-$-11.47M
Capital expenditure-$-20K$0.00-$-80K-$-30K-$-50K
Free cash flow-$-16.83M-$-21.72M-$-20.75M-$-17.92M-$-11.52M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lifeward Ltd.

        Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.

        CEO
        William Mark Grant
        Employees
        81
        Beta
        0.37

        Explore

        Frequently asked questions

        What is the intrinsic value of Lifeward Ltd. (LFWD)?

        Lifeward Ltd. (LFWD) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LFWD undervalued?

        LFWD trades at a price of $2.80 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.